To address this gap, we conducted a retrospective cohort study evaluating the risk of new‐onset NASH and liver cirrhosis in patients treated with GLP‐1 RAs versus those who underwent bariatric surgery. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.